Print

Syrrx, Inc. Receives Second And Third Success Payments And Announces Completion Of Research Agreement With Biogen Idec, Inc. (Massachusetts) (BIIB) 
10/19/2005 5:11:01 PM

Syrrx Inc., a next generation structure-based drug discovery company, today announced the receipt of the second and third success-based milestone payments from Biogen Idec (Nasdaq:BIIB). These payments follow on the heels of the first success payment to Syrrx on May 27th, 2004. The collaboration applies Syrrx's expertise in high-throughput crystallization of proteins across multiple Biogen Idec drug targets. Financial terms were not disclosed.